search
Back to results

Effects of Breaking up Sitting Time on Cardiometabolic Risk Markers and Cardiac Function Post Myocardial Infarction (MOVE-MI)

Primary Purpose

Cardiovascular Diseases

Status
Recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Prolonged sitting
Sponsored by
University of Bedfordshire
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Cardiovascular Diseases

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients post myocardial infarction (ST wave elevated MI or Non-ST wave elevated MI) within the past three months (confirmed by elevated blood biomarkers or electrocardiographic changes), in which the procedure/ recovery uncomplicated and are therefore classified as low risk.
  • Aged 40 years or above.
  • Any ethnicity.
  • Individuals with diet controlled type 2 diabetes mellitus

Exclusion Criteria:

  • Previous MI
  • Under 40 years of age.
  • Unable to provide valid informed consent (lack of mental capacity).
  • Not had a cardiac event diagnosed within the past three months.
  • Existing comorbidities including cancer, chronic kidney disease and gastro-oesophageal diseases.
  • Unstable coronary disease.
  • Diagnosed diabetes and use of medication.
  • Disease or conditions with a prognosis of less than 6 months to end of life (palliative care). Any known blood borne disease.
  • Unable to stand and engage in light-intensity stepping.

Sites / Locations

  • Cardiac RehabilitationRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Prolonged sitting

Sitting interrupted with standing

Sitting interrupted with light stepping

Arm Description

Uninterrupted sitting for 6 hours.

Sitting interrupted with 5 minutes of static standing every 30 minutes for 6 hours.

Sitting interrupted with 5 minutes of light intensity stepping every 30 minutes using a metronome at the intensity determined during preliminary testing. This replicates active recovery time currently performed in a phase III CR class.

Outcomes

Primary Outcome Measures

Posterior wall thickness
Posterior wall thickness in cm
Interventricular septum
Interventricular septum in cm
Left ventricular internal diameter
Left ventricular internal diameter in cm
Aortic root
Aortic root in cm
End volume
End volume in cm
E wave
E wave in ms
A wave
A wave in ms
Relative wall thickness
Relative wall thickness in cm
Left ventricular mass
Left ventricular mass in g
E/A ratio
E/A ratio
Deceleration time
Deceleration time in ms
Isovolumetric relaxation time
Isovolumetric relaxation time in ms
Ejection fraction
Ejection fraction in %
Stroke volume
Stroke volume in L

Secondary Outcome Measures

Systolic Blood pressure
Resting systolic blood pressure in mmHg
Diastolic Blood pressure
Resting diastolic blood pressure in mmHg
Postprandial triglycerides
Postprandial triglycerides in mmol/L
Postprandial total cholesterol
Postprandial total cholesterol in mmol/L
Postprandial low density lipoprotein cholesterol
Postprandial low density lipoprotein cholesterol in mmol/L
Postprandial high density lipoprotein cholesterol
Postprandial high density lipoprotein cholesterol in mmol/L
Postprandial insulin
Postprandial insulin in mU/L
Postprandial glucose
Postprandial glucose in mmol/L
Mood and wellbeing
Positive affect and negative affect scale. This is a 5 point score, that asks 10 questions about positive feelings and 10 questions about negative feelings. The higher the score for each scale, the more likely they are feeling positive or negative.

Full Information

First Posted
December 6, 2021
Last Updated
March 2, 2023
Sponsor
University of Bedfordshire
search

1. Study Identification

Unique Protocol Identification Number
NCT05193175
Brief Title
Effects of Breaking up Sitting Time on Cardiometabolic Risk Markers and Cardiac Function Post Myocardial Infarction
Acronym
MOVE-MI
Official Title
Effects of Breaking up Sitting Time on Cardiometabolic Risk Markers and Cardiac Function Post Myocardial Infarction
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 29, 2021 (Actual)
Primary Completion Date
April 30, 2023 (Anticipated)
Study Completion Date
June 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Bedfordshire

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Cardiovascular Disease (CVD) is one of the greatest causes of mortality and morbidity globally, particularly in middle to high income countries. In the UK alone, it was accountable for 124,641 deaths in 2017. Further to this, CVD contributes to a vast economic burden, costing the National Health Service (NHS) £19billion annually. This is mainly due to a significant number of hospital readmissions following a first cardiac event (198,000 per annum). Following a cardiac event, an individual is therefore recommended to reduce their risk factors, including lipid profile, smoking status and physical inactivity, to reduce their risk of a secondary event. In healthy individuals, regularly breaking up sitting time reduces cardiometabolic risk markers. The aim of this study is to therefore observe if this effect is replicated in the cardiac population and thus whether breaking up sitting time will reduce the risk of a secondary cardiac event. Potential participants will be required to meet an inclusion criteria to take part in the study: aged 50 years or above and had a myocardial infarction within the past three months at the time of recruitment to the study. Participants will be randomised to each condition: 1) uninterrupted sitting; 2) sitting with intermittent standing and 3) sitting with intermittent light physical activity (stepping to a metronome beat). A number of physiological markers will be measured before, during and after each condition and analysed to compare the effectiveness of each condition. All measurements will be taken at the University of Bedfordshire Sport and Exercise Science Laboratories.
Detailed Description
Study design A repeated measures, randomised cross over study design will be used. All data collection will take place at the Sport and Exercise Science Laboratories, University of Bedfordshire, Polhill Avenue, Bedford, UK. After a preliminary testing session, participants will complete three, 6-hour experimental conditions in a random order: 1) uninterrupted sitting; 2) sitting interrupted with standing breaks, and 3) sitting interrupted with light intensity stepping breaks. There will be a washout period of at least 72 hours between conditions, as previous research suggests that a single session of exercise can affect blood glucose levels for the following 48 hours (Mikines, et al., 1988). Participants will be randomised to order of condition using computer generated random numbers. This will assign them a trial order using block randomization with balanced block sizes. Participants will be blinded to the trial condition until they arrive on the day of their first and second experimental conditions. Preliminary testing Patients will first attend a preliminary testing session where they will become accustomed to light intensity stepping on the spot to the beat of a metronome and use of the Borg RPE scale. This will ensure patients are familiar with an intensity that is equivalent to an RPE of 8-11 (very light to light) that will be used in the respective experimental condition. Participants will step to different metronome paces starting at a slow pace and building up gradually every 1-2 minutes until an RPE of 8-11 is found. This imitates the intensity recommended within the warm up of CR, as recommended by BACPR. Height (cm) and weight (kg) will also be measured using a stadiometer (Harpenden 98.602, Holtain Ltd., Crymych) and digital scales (Tanita BWB0800, Tanita Corp., Tokyo, Japan) respectively, to calculate body mass index (kg/m2). Experimental Protocol Participants will be asked to refrain from any alcohol and caffeine for 24 hours prior to each visit, as well as avoid exercise for 72 hours and complete an overnight fast. This will be explained to them during the preliminary visit. To monitor this, they will be asked prior to participation per visit whether they have fasted/ when they last ate and drank. Participants will be asked to perform an overnight fast for at least 10 hours before arrival and minimise active travel to the laboratory (e.g. use a car for travel). They will rest for 30 minutes to achieve a steady state before baseline blood pressure (two measures with 2 minutes rest between each and the average taken) and blood samples are taken. Baseline cardiac function measures (global strain, ejection fraction and systolic volume) will be measured using an echocardiogram scan, as well as an electrocardiogram (ECG) to ensure there are no electrical contraindications to the heart which would make the participant unsuitable to complete the study intervention including ST depression / elevation or any arrythmias. Baseline mood and wellbeing measures will then be assessed using questionnaires. Following baseline measures, a standardised breakfast will be consumed (see meals section below) and participants will then commence the experimental condition. See Figure 1 for schematic of experimental conditions. The three experimental conditions for this study are: Uninterrupted sitting for 6 hours. Sitting interrupted with 5 minutes of static standing every 30 minutes. Sitting interrupted with 5 minutes of light intensity stepping every 30 minutes using a metronome at the intensity determined during preliminary testing. This replicates active recovery time currently performed in a phase III CR class. A lunch meal will be provided at 12:00 during each condition. During sitting periods, participants will be able to read books, magazines or newspapers and/or watch TV, DVDs or media streaming services. Participants will be transported to the toilets and food consumption areas using a wheelchair to ensure activity is minimised and standardised between conditions. Standardised food and water intake Each meal will provide approximately 30% of estimated daily energy requirements. This will be calculated for each individual participant using a prediction equation based on individual's height, weight and gender. Breakfast will consist of bran flakes, whole milk, and a honey and granola bar and will consist of 54% carbohydrate, 34% fat and 12% protein. Lunch will consist of a chicken sandwich, salted crisps and jammie dodger biscuit (54% carbohydrate, 34% fat and 12% protein). The macronutrient composition of the meals are in general agreement with guidelines recommended for a balanced diet (Public Health England, 2016). Participants will be encouraged to consume their meal within 15 minutes. The time taken will be recorded in the first condition and this time will then be replicated in the latter two conditions. Water will be available for the participants ad libitum during their first experimental condition visit. This volume of intake will be recorded and the same amount provided in the following two conditions spread over the day. Data collection Finger prick capillary whole blood samples will be collected at baseline, 30, 60, 120, 180, 210, 240, 300 and 360 minutes throughout the conditions to allow later analysis of glucose, triglycerides, HDL-C, and insulin. Blood samples will be taken after the hand is pre-warmed in warm water for approximately 5 minutes. Blood pressure and heart rate will be measured 5 minutes before each of the blood samples are taken. Cardiac function measures and mood and wellbeing will be measured at baseline and post-condition.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiovascular Diseases

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Randomized
Enrollment
18 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Prolonged sitting
Arm Type
Experimental
Arm Description
Uninterrupted sitting for 6 hours.
Arm Title
Sitting interrupted with standing
Arm Type
Experimental
Arm Description
Sitting interrupted with 5 minutes of static standing every 30 minutes for 6 hours.
Arm Title
Sitting interrupted with light stepping
Arm Type
Experimental
Arm Description
Sitting interrupted with 5 minutes of light intensity stepping every 30 minutes using a metronome at the intensity determined during preliminary testing. This replicates active recovery time currently performed in a phase III CR class.
Intervention Type
Behavioral
Intervention Name(s)
Prolonged sitting
Other Intervention Name(s)
Sitting interrupted with standing, Sitting interrupted with light stepping
Intervention Description
Cross over design, where participants will take part in all three interventions listed above: 1) uninterrupted sitting, 2) sitting interrupted with standing and 3) sitting interrupted with light stepping
Primary Outcome Measure Information:
Title
Posterior wall thickness
Description
Posterior wall thickness in cm
Time Frame
4 months
Title
Interventricular septum
Description
Interventricular septum in cm
Time Frame
4 months
Title
Left ventricular internal diameter
Description
Left ventricular internal diameter in cm
Time Frame
4 months
Title
Aortic root
Description
Aortic root in cm
Time Frame
4 months
Title
End volume
Description
End volume in cm
Time Frame
4 months
Title
E wave
Description
E wave in ms
Time Frame
4 months
Title
A wave
Description
A wave in ms
Time Frame
4 months
Title
Relative wall thickness
Description
Relative wall thickness in cm
Time Frame
4 months
Title
Left ventricular mass
Description
Left ventricular mass in g
Time Frame
4 months
Title
E/A ratio
Description
E/A ratio
Time Frame
4 months
Title
Deceleration time
Description
Deceleration time in ms
Time Frame
4 months
Title
Isovolumetric relaxation time
Description
Isovolumetric relaxation time in ms
Time Frame
4 months
Title
Ejection fraction
Description
Ejection fraction in %
Time Frame
4 months
Title
Stroke volume
Description
Stroke volume in L
Time Frame
4 months
Secondary Outcome Measure Information:
Title
Systolic Blood pressure
Description
Resting systolic blood pressure in mmHg
Time Frame
4 months
Title
Diastolic Blood pressure
Description
Resting diastolic blood pressure in mmHg
Time Frame
4 months
Title
Postprandial triglycerides
Description
Postprandial triglycerides in mmol/L
Time Frame
4 months
Title
Postprandial total cholesterol
Description
Postprandial total cholesterol in mmol/L
Time Frame
4 months
Title
Postprandial low density lipoprotein cholesterol
Description
Postprandial low density lipoprotein cholesterol in mmol/L
Time Frame
4 months
Title
Postprandial high density lipoprotein cholesterol
Description
Postprandial high density lipoprotein cholesterol in mmol/L
Time Frame
4 months
Title
Postprandial insulin
Description
Postprandial insulin in mU/L
Time Frame
4 months
Title
Postprandial glucose
Description
Postprandial glucose in mmol/L
Time Frame
4 months
Title
Mood and wellbeing
Description
Positive affect and negative affect scale. This is a 5 point score, that asks 10 questions about positive feelings and 10 questions about negative feelings. The higher the score for each scale, the more likely they are feeling positive or negative.
Time Frame
4 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients post myocardial infarction (ST wave elevated MI or Non-ST wave elevated MI) within the past three months (confirmed by elevated blood biomarkers or electrocardiographic changes), in which the procedure/ recovery uncomplicated and are therefore classified as low risk. Aged 40 years or above. Any ethnicity. Individuals with diet controlled type 2 diabetes mellitus Exclusion Criteria: Previous MI Under 40 years of age. Unable to provide valid informed consent (lack of mental capacity). Not had a cardiac event diagnosed within the past three months. Existing comorbidities including cancer, chronic kidney disease and gastro-oesophageal diseases. Unstable coronary disease. Diagnosed diabetes and use of medication. Disease or conditions with a prognosis of less than 6 months to end of life (palliative care). Any known blood borne disease. Unable to stand and engage in light-intensity stepping.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Abbie C Bell, MSc
Phone
07984545911
Email
abbie.bell@study.beds.ac.uk
First Name & Middle Initial & Last Name or Official Title & Degree
Joanna Richards, PhD
Phone
01234400400
Email
jo.richards@beds.ac.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joanna Richards, PhD
Organizational Affiliation
University of Bedfordshire
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Abbie C Bell, MSc
Organizational Affiliation
Bedfordshire Hospitals NHS Foundation Trust
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cardiac Rehabilitation
City
Bedford
State/Province
Bedfordshire
ZIP/Postal Code
MK429DJ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Abbie Bell, MSc
Phone
07984545911
Email
abbie.bell@study.beds.ac.uk
First Name & Middle Initial & Last Name & Degree
Joanna Richards, PhD
Phone
01234 400400
Email
jo.richards@beds.ac.uk

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Upon registration to the study, participants will be given a unique participant ID number, which will henceforth be used in all data collection within the study. This will be determined using a number system. A confidential log will be kept by the research team to identify participants with their anonymous ID numbers, which will be encrypted on a secure computer. All other electronic documentation will also be encrypted. Only direct members of the research team will have access to the data, and will be listed on the study's delegation log. Where data is transmitted to sponsors, if necessary, it will only be identifiable by its participant ID number, thus not becoming patient identifiable at any time.

Learn more about this trial

Effects of Breaking up Sitting Time on Cardiometabolic Risk Markers and Cardiac Function Post Myocardial Infarction

We'll reach out to this number within 24 hrs